Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohanad M Al-Obaidi

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Open Forum Infectious Diseases|August 27, 2024
Clinical Characteristics and Mortality Risks Among Patients With Culture-Proven Coccidioidomycosis Who Are Critically Ill: A Multicenter Study in an Endemic RegionJames Lim, Ashley M Scott, Rebecca Wig, et al.
Plos Pathogens|January 5, 2023
Race and ethnicity: Risk factors for fungal infections?Jeffrey D Jenks, Chioma Inyang Aneke, Mohanad M Al-Obaidi, et al.
The American Journal of Medicine|March 10, 2023
The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant EraMohanad M Al-Obaidi, Ahmet B Gungor, Sangeetha Murugapandian, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2021
Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the AntibioticAna Paula Streling, Mohanad M Al Obaidi, William D Lainhart, et al.
Expert Opinion on Investigational Drugs|June 3, 2022
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of actionMartin Hoenigl, Rosanne Sprute, Amir Arastehfar, et al.
Open Forum Infectious Diseases|July 6, 2022
Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) InfectionMohanad M Al-Obaidi, Ahmet B Gungor, Saman Nematollahi, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Open Forum Infectious Diseases|August 27, 2024
Clinical Characteristics and Mortality Risks Among Patients With Culture-Proven Coccidioidomycosis Who Are Critically Ill: A Multicenter Study in an Endemic RegionJames Lim, Ashley M Scott, Rebecca Wig, et al.
Plos Pathogens|January 5, 2023
Race and ethnicity: Risk factors for fungal infections?Jeffrey D Jenks, Chioma Inyang Aneke, Mohanad M Al-Obaidi, et al.
The American Journal of Medicine|March 10, 2023
The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant EraMohanad M Al-Obaidi, Ahmet B Gungor, Sangeetha Murugapandian, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2021
Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the AntibioticAna Paula Streling, Mohanad M Al Obaidi, William D Lainhart, et al.
Expert Opinion on Investigational Drugs|June 3, 2022
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of actionMartin Hoenigl, Rosanne Sprute, Amir Arastehfar, et al.
Open Forum Infectious Diseases|July 6, 2022
Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) InfectionMohanad M Al-Obaidi, Ahmet B Gungor, Saman Nematollahi, et al.
Pageof 2